{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T02:33:27Z","timestamp":1794882807151,"version":"4.9.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>This comprehensive review aimed to evaluate the efficacy and safety of combining laser or light therapy with topical agents for melasma treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A comprehensive search was conducted utilizing PubMed, NCBI, Google Scholar, ScienceDirect, Wiley, Embase, and the Cochrane Library. The search aimed to identify pertinent studies from the database\u2019s inception until August 31, 2024. This research encompassed 11 randomized controlled trials including 461 people. The melasma area and severity index and its modified variant (mMASI) were employed for outcome assessment. The Cochrane risk-of-bias tool was used to assess study quality. The GRADE (grading of recommendations assessment, development and evaluation) approach was employed to assess the certainty of evidence. Sensitivity analyses were performed to evaluate the robustness of findings. Data were analyzed using RevMan 5.4.1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Combination therapy demonstrated no significant benefit at 4 weeks, but statistically significant improvements at 8, 12, and 16 weeks (standardized mean difference [SMD]: \u22120.55; 95% confidence interval: \u22120.74 to \u22120.36;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.00001), indicating a cumulative therapeutic effect. Moderate heterogeneity was observed (\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u200564%). Sensitivity analysis excluding parallel-design studies (Souza, Bansal, Verma, Qu) confirmed the robustness of efficacy outcomes, with a similar effect size (SMD: \u22120.45) and reduced heterogeneity (\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005\u2248\u200541%). Safety analysis showed a significantly higher risk of adverse events in the combination group (OR: 8.96; 95% confidence interval: 3.71\u201321.64), mainly erythema and post-inflammatory hyperpigmentation. The certainty of evidence was rated as moderate for efficacy and very low for safety outcomes. Both were judged critically important (importance score 9 and 8, respectively) for clinical decision-making.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These findings suggest that combination therapy can effectively enhance melasma treatment. However, careful patient selection and monitoring are crucial due to the risk of side effects. Further large-scale studies with standardized protocols are recommended to validate these findings and optimize treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000046579","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:02:13Z","timestamp":1767988933000},"page":"e46579","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Laser and light-based therapies combined with topical agents for melasma: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2843-5463","authenticated-orcid":false,"given":"Risha Fillah","family":"Fithria","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China"},{"name":"Faculty of Pharmacy, Universitas Wahid Hasyim, Semarang, Middle Java, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0492-2398","authenticated-orcid":false,"given":"Yehuda Tri Nugroho","family":"Supranoto","sequence":"additional","affiliation":[{"name":"Bioinformatics Research Center, Institute of Bioinformatics (INBIO), Malang, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5724-1516","authenticated-orcid":false,"given":"Zhaoqian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China"},{"name":"Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Xiangya Hospital, Central South University, Changsha, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4516-2030","authenticated-orcid":false,"given":"Jinfu","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260805","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/der2.178","article-title":"Pathogenesis of melasma.","volume":"4","author":"Khanna","year":"2023","journal-title":"Dermatol Rev"},{"key":"R2-20260805","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s13555-017-0194-1","article-title":"Melasma:an up-to-date comprehensive review.","volume":"7","author":"Ogbechie-Godec","year":"2017","journal-title":"Dermatol Ther"},{"key":"R3-20260805","first-page":"86","article-title":"Prevalence problem of chloasma and melasma at women.","volume":"5","author":"Kurbanova","year":"2019","journal-title":"Bulletin Sci Pract"},{"key":"R4-20260805","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2147\/CCID.S396272","article-title":"New mechanistic insights of melasma.","volume":"16","author":"Liu","year":"2023","journal-title":"Clin Cosmetic Investig Dermatol"},{"key":"R5-20260805","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4103\/2349-5847.219683","article-title":"Impact of melasma on quality of life in Indian patients.","volume":"4","author":"Arora","year":"2017","journal-title":"Pigment Int"},{"key":"R6-20260805","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s13555-023-00915-1","article-title":"Self-esteem, depression, anxiety and quality of life in patients with melasma living in a sunny mediterranean area: results from a prospective cross-sectional study.","volume":"13","author":"Platsidaki","year":"2023","journal-title":"Dermatol Ther"},{"key":"R7-20260805","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1111\/jocd.16006","article-title":"Efficacy and safety of laser\u2010related therapy for melasma: a systematic review and network meta\u2010analysis.","volume":"22","author":"Ma","year":"2023","journal-title":"J Cosmet Dermatol"},{"key":"R8-20260805","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/lsm.23615","article-title":"Combination of a 755\u2010nm picosecond laser and hydroquinone 2% cream versus hydroquinone 2% cream alone for the treatment of melasma: a randomized, split\u2010face, and controlled trial.","volume":"54","author":"Manuskiatti","year":"2022","journal-title":"Lasers Surg Med"},{"key":"R9-20260805","first-page":"1","article-title":"Q-switched laser combined with intense pulsed laser in the treatment of melasma based on reflection confocal microscope.","volume":"2022","author":"Xu","year":"2022","journal-title":"Comput Math Methods Med"},{"key":"R10-20260805","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.3390\/jcm13051468","article-title":"Management of melasma: laser and other therapies\u2014review study.","volume":"13","author":"Jiryis","year":"2024","journal-title":"J Clin Med"},{"key":"R11-20260805","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1111\/jocd.16464","article-title":"Efficacy, safety, tolerability and treatment durability of microneedling plus topical tranexamic acid in combination with topical modified Kligman lightening formula for melasma: a four\u2010arm assessor and analyst blinded randomized controlled clinical trial.","volume":"23","author":"Aghdam","year":"2024","journal-title":"J Cosmet Dermatol"},{"key":"R12-20260805","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s40257-024-00863-2","article-title":"An update on new and existing treatments for the management of melasma.","volume":"25","author":"Gan","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"R13-20260805","doi-asserted-by":"crossref","first-page":"i70","DOI":"10.1093\/bjd\/ljae090.141","article-title":"BC01 Evaluation of effectiveness of fractional ablative CO2 laser and triple combination cream in the treatment of melasma: a randomized controlled study.","volume":"191","author":"Verma","year":"2024","journal-title":"Br J Dermatol"},{"key":"R14-20260805","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R17-20260805","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1529-8019.2012.01530.x","article-title":"Single-session intense pulsed light combined with stable fixed-dose triple combination topical therapy for the treatment of refractory melasma.","volume":"25","author":"Souza","year":"2012","journal-title":"Dermatol Ther"},{"key":"R18-20260805","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4103\/0974-2077.104915","article-title":"A comparison of low-fluence 1064-nm Q-switched Nd: YAG laser with topical 20% azelaic acid cream and their combination in melasma in Indian patients.","volume":"5","author":"Bansal","year":"2012","journal-title":"J Cutaneous Aesthetic Surg"},{"key":"R20-20260805","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3126\/njdvl.v19i2.38557","article-title":"Efficacy of intense pulse light with triple combination cream versus triple combination cream alone in the treatment of melasma.","volume":"19","author":"Verma","year":"2021","journal-title":"Nepal J Dermatol Venereol Leprol"},{"key":"R21-20260805","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/jocd.13992","article-title":"Clinical observation and dermoscopy evaluation of fractional CO2 laser combined with topical tranexamic acid in melasma treatments.","volume":"20","author":"Qu","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"R22-20260805","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/archdermatol.2011.255","article-title":"Melasma treatment with pulsed-dye laser and triple combination cream: a prospective, randomized, single-blind, split-face study.","volume":"147","author":"Passeron","year":"2011","journal-title":"Arch Dermatol"},{"key":"R23-20260805","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/CCID.S147413","article-title":"Fractional erbium-doped yttrium aluminum garnet laser-assisted drug delivery of hydroquinone in the treatment of melasma.","volume":"11","author":"Badawi","year":"2018","journal-title":"Clin Cosmetic Investig Dermatol"},{"key":"R24-20260805","doi-asserted-by":"crossref","first-page":"70","DOI":"10.15171\/jlms.2020.12","article-title":"The split-face comparison of the combined Er-YAG laser and hydroquinone 4% with hydroquinone 4% alone in the treatment of melasma in Iranian patients: a prospective, interventional case study.","volume":"11","author":"Namazi","year":"2020","journal-title":"J Lasers Med Sci"},{"key":"R25-20260805","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/14764172.2021.1964536","article-title":"Evaluation of the of the efficacy of fractional erbium-doped yttrium aluminum garnet laser-assisted drug delivery of kojic acid in the treatment of melasma; a split face, comparative clinical study.","volume":"23","author":"Al-Dhalimi","year":"2021","journal-title":"J Cosmetic Laser Ther"},{"key":"R26-20260805","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00403-021-02294-z","article-title":"A split-face comparison of fractional erbium: YAG laser plus Kligman\u2019s formula vs. Kligman\u2019s formula monotherapy for facial melasma.","volume":"314","author":"Nasimi","year":"2022","journal-title":"Arch Dermatol Res"},{"key":"R27-20260805","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1111\/jocd.15641","article-title":"Comparative effectiveness and safety of topical methimazole 5% monotherapy versus combination of Q-Switched Nd: YAG laser and topical methimazole 5% in patients with refractory melasma.","volume":"22","author":"Beyzaee","year":"2023","journal-title":"J Cosmet Dermatol"},{"key":"R28-20260805","doi-asserted-by":"crossref","first-page":"l5221","DOI":"10.1136\/bmj.l5221","article-title":"Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.","volume":"366","author":"Naci","year":"2019","journal-title":"BMJ"},{"key":"R29-20260805","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.sder.2009.04.001","article-title":"Management of hyperpigmentation in darker racial ethnic groups.","volume":"28","author":"Grimes","year":"2009","journal-title":"Semin Cutan Med Surg"},{"key":"R30-20260805","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4103\/0019-5154.174024","article-title":"Proposing melasma severity index: a new, more practical, office-based scoring system for assessing the severity of melasma.","volume":"61","author":"Majid","year":"2016","journal-title":"Indian J Dermatol"},{"key":"R31-20260805","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijwd.2017.01.004","article-title":"A review of laser and light therapy in melasma.","volume":"3","author":"Trivedi","year":"2017","journal-title":"Int J Women\u2019s Dermatol"},{"key":"R32-20260805","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/lsm.23723","article-title":"Melasma treatment with a 1064\u2009nm, picosecond\u2010domain laser with a fractionated multibeam lens array.","volume":"55","author":"Bernstein","year":"2023","journal-title":"Lasers Surg Med"},{"key":"R33-20260805","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4103\/JCAS.JCAS_179_18","article-title":"Laser toning in melasma.","volume":"12","author":"Shah","year":"2019","journal-title":"J Cutaneous Aesthet Surg"},{"key":"R34-20260805","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40257-013-0038-4","article-title":"Treatment of melasma with topical agents, peels and lasers: an evidence-based review.","volume":"14","author":"Rivas","year":"2013","journal-title":"Am J Clin Dermatol"},{"key":"R35-20260805","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.2147\/CCID.S372456","article-title":"Melasma: a step-by-step approach towards a multimodal combination therapy.","volume":"17","author":"Philipp-Dormston","year":"2024","journal-title":"Clin Cosmetic Investig Dermatol"},{"key":"R36-20260805","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2147\/CCID.S267203","article-title":"Updates and best practices in the management of facial erythema.","volume":"14","author":"Loyal","year":"2021","journal-title":"Clin Cosmetic Investig Dermatol"},{"key":"R37-20260805","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/pcmr.12986","article-title":"Management of hyperpigmentation: current treatments and emerging therapies.","volume":"34","author":"Nautiyal","year":"2021","journal-title":"Pigment Cell Melanoma Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T17:01:49Z","timestamp":1785949309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046579","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"2025-01-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}